摘要
患者确诊为急性髓系白血病伴有CEBPA双突变、GATA2、IKZF1突变,给予2个疗程的IA方案(去甲氧柔红霉素、阿糖胞苷)治疗后复发,又给予4个疗程的阿扎胞苷联合venetodax治疗出现短暂缓解,后因未规律治疗再次复发。本文主要分析CEBPA双突变联合GATA2种系突变在急性髓系白血病中的治疗及预后作用。
The patient was diagnosed as acute myeloid leukaemia with CEBPA double mutation,GATA2 and IKZF1 mutation in 2021,and relapsed after giving two courses of IA treatment(idarubicin,cytosine arabinoside).There was transient remission after four additional courses of azacitidine combined with venetoclax.The patient relapsed again due to lack of regular treatment.This paper mainly analyses the therapeutic and prognostic role of CEBPA double mutation combined with GATA2 germline mutation in acute myeloid leukaemia.
作者
安慧慧
吴涛
李芸芸
刘文慧
田思锐
刘洋
高铭敏
AN Huihui;WU Tao;LI Yunyun;LIU Wenhui;TIAN Sirui;LIU Yang;GAO Mingmin(The Second Hospital of Lanzhou University(the Second Clinical Medical College),Lanzhou 730030,China;Departmentof Hematology,the 940th Hospital of the Joint Logistics Support Force of Chinese People’s Liberation Army,Lanzhou 730050,China)
出处
《内科理论与实践》
2024年第3期185-187,共3页
Journal of Internal Medicine Concepts & Practice
基金
甘肃省科技计划(创新基地和人才计划)项目(21JR7RA015)
甘肃省科技计划项目(22YF7FA106)
联勤保障部队第九四〇医院科研项目(2021yxky078)。
